Condition: Bipolar Depression · Suicidal Ideation and Behavior · Sponsor: NeuroRx, Inc.
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression with suicidal ideation. This study will test the hypothesis that NRX-101 is superior to lurasidone alone (standard of care) in maintaining remission from symptoms of depression (primary endpoint) and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Science 37 | Culver City, California, United States | — |
| San Marcus Research Clinic, Inc. | Miami Lakes, Florida, United States | — |
| ACMR | Atlanta, Georgia, United States | — |
| iResearch Atlanta, LLC | Decatur, Georgia, United States | — |
| iResearch Savannah | Savannah, Georgia, United States | — |
| CBH Health | Gaithersburg, Maryland, United States | — |
| Omaha Insomnia and Psychiatric Services | Omaha, Nebraska, United States | — |
| Dent Neurologic Institute | Amherst, New York, United States | — |
| Peace Health Medical Group | Eugene, Oregon, United States | — |
| University of Texas Health Austin | Austin, Texas, United States | — |
| Roots Behavioral Health | Austin, Texas, United States | — |
| JPS Health | Fort Worth, Texas, United States | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03395392